WuXi Biologics Cayman saw the highest growth of 0.92% in patent filings in May and 1.74% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.86% and grants by 1.74%. GlobalData’s DataBook provides a comprehensive analysis of WuXi Biologics Cayman’s patent filings and grants. Buy the databook here.
WuXi Biologics Cayman has been focused on protecting inventions in China(CN) with 24 publications in Q2 2024
The China(CN) Patent Office dominates the patent filings and grants with nearly 44% filings and 56% grants. The China(CN), United States(US), Israel(IL), and Japan(JP) patent Office are among the top ten patent offices where WuXi Biologics Cayman is filings its patents. Among the top granted patent authorities, WuXi Biologics Cayman has 56% of its grants in China(CN), 19% in Japan(JP) and 12% in Israel(IL).
Roche and Johnson & Johnson could be the strongest competitors for WuXi Biologics Cayman
Patents related to industrial automation and genomics lead WuXi Biologics Cayman's portfolio
WuXi Biologics Cayman has the highest number of patents in industrial automation followed by, genomics and robotics. For industrial automation, nearly 50% of patents were filed and 100% of patents were granted in Q2 2024.
Viral infections related patents lead WuXi Biologics Cayman portfolio followed by packaging, and alarms and signalling equipment
WuXi Biologics Cayman has highest number of patents in viral infections followed by packaging, alarms and signalling equipment, cell therapy, and hemorrhage. For viral infections, nearly 40% of patents were filed and 25% of patents were granted in Q2 2024.
For comprehensive analysis of WuXi Biologics Cayman's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.